Bacteria Engineered to Produce IL-22 in Intestine Induce Expression of REG3G to Reduce Ethanol-induced Liver Disease in Mice
Overview
Authors
Affiliations
Objective: Antimicrobial C-type lectin regenerating islet-derived 3 gamma (REG3G) is suppressed in the small intestine during chronic ethanol feeding. Our aim was to determine the mechanism that underlies REG3G suppression during experimental alcoholic liver disease.
Design: Interleukin 22 (IL-22) regulates expression of REG3G. Therefore, we investigated the role of IL-22 in mice subjected to chronic-binge ethanol feeding (NIAAA model).
Results: In a mouse model of alcoholic liver disease, we found that type 3 innate lymphoid cells produce lower levels of IL-22. Reduced IL-22 production was the result of ethanol-induced dysbiosis and lower intestinal levels of indole-3-acetic acid (IAA), a microbiota-derived ligand of the aryl hydrocarbon receptor (AHR), which regulates expression of IL-22. Importantly, faecal levels of IAA were also found to be lower in patients with alcoholic hepatitis compared with healthy controls. Supplementation to restore intestinal levels of IAA protected mice from ethanol-induced steatohepatitis by inducing intestinal expression of IL-22 and REG3G, which prevented translocation of bacteria to liver. We engineered to produce IL-22 (/IL-22) and fed them to mice along with the ethanol diet; these mice had reduced liver damage, inflammation and bacterial translocation to the liver compared with mice fed an isogenic control strain and upregulated expression of REG3G in intestine. However, /IL-22 did not reduce ethanol-induced liver disease in mice.
Conclusion: Ethanol-associated dysbiosis reduces levels of IAA and activation of the AHR to decrease expression of IL-22 in the intestine, leading to reduced expression of REG3G; this results in bacterial translocation to the liver and steatohepatitis. Bacteria engineered to produce IL-22 induce expression of REG3G to reduce ethanol-induced steatohepatitis.
Metabolic engineering of Lactobacilli spp. for disease treatment.
Yang Y, Yu P, Huang Y, Zhang W, Nie Y, Gao C Microb Cell Fact. 2025; 24(1):53.
PMID: 40050843 PMC: 11887175. DOI: 10.1186/s12934-025-02682-4.
The gut microbiota: an emerging modulator of drug resistance in hepatocellular carcinoma.
Yao J, Ning B, Ding J Gut Microbes. 2025; 17(1):2473504.
PMID: 40042184 PMC: 11901387. DOI: 10.1080/19490976.2025.2473504.
Oral delivery of therapeutic proteins by engineered bacterial type zero secretion system.
Gong X, Liu S, Xia B, Wan Y, Zhang S, Zhang B Nat Commun. 2025; 16(1):1862.
PMID: 39984501 PMC: 11845744. DOI: 10.1038/s41467-025-57153-6.
Current and emerging therapies for alcohol-associated hepatitis.
Idalsoaga F, Ayares G, Diaz L, Arnold J, Ayala-Valverde M, Hudson D Liver Res. 2025; 7(1):35-46.
PMID: 39959695 PMC: 11792060. DOI: 10.1016/j.livres.2023.03.002.
Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions.
Zhao Q, Wu J, Ding Y, Pang Y, Jiang C Life Metab. 2025; 2(6):load032.
PMID: 39872860 PMC: 11749371. DOI: 10.1093/lifemeta/load032.